Organon & Co. Gross Profit
Organon & Co. (OGN) reported Gross Profit of $847.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement
us-gaap:GrossProfit · last filed 2026-07-31
- Organon & Co. gross profit for the quarter ending 2026-06-30 was $847.00M, a 3.09% decline year-over-year.
- Organon & Co. gross profit for the quarter ending 2026-03-31 was $783.00M, a 6.90% decline year-over-year.
- Organon & Co. gross profit for the quarter ending 2025-12-31 was $741.00M, a 17.30% decline year-over-year.
- Organon & Co. gross profit for the quarter ending 2025-09-30 was $857.00M, a 7.15% decline year-over-year.
- Organon & Co. gross profit for fiscal 2025 was $3.31B, a 10.82% decline from fiscal 2024.
- Organon & Co. gross profit for fiscal 2024 was $3.71B, a 0.88% decline from fiscal 2023.
- Organon & Co. gross profit for fiscal 2023 was $3.75B, a 3.40% decline from fiscal 2022.
- Organon & Co. gross profit for fiscal 2022 was $3.88B.
| Period end | Gross Profit 3 month | Gross Profit 6 month | Gross Profit 9 month | Gross Profit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $847.00M 10-Q · filed 2026-07-31 | $1.63B 10-Q · filed 2026-07-31 | $2.37B derived: sum of 3 quarters · filed 2026-07-31 | $3.23B derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $783.00M 10-Q · filed 2026-05-04 | $1.52B derived: sum of 2 quarters · filed 2026-05-04 | $2.38B derived: sum of 3 quarters · filed 2026-05-04 | $3.25B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $741.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.60B derived: sum of 2 quarters · filed 2026-02-24 | $2.47B derived: sum of 3 quarters · filed 2026-07-31 | $3.31B 10-K · filed 2026-02-24 |
| 2025-09-30 | $857.00M 10-Q · filed 2025-11-10 | $1.73B derived: sum of 2 quarters · filed 2026-07-31 | $2.57B 10-Q · filed 2025-11-10 | $3.47B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $874.00M 10-Q · filed 2026-07-31 | $1.72B 10-Q · filed 2026-07-31 | $2.61B derived: sum of 3 quarters · filed 2026-07-31 | $3.53B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $841.00M 10-Q · filed 2026-05-04 | $1.74B derived: sum of 2 quarters · filed 2026-05-04 | $2.66B derived: sum of 3 quarters · filed 2026-05-04 | $3.60B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $896.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.82B derived: sum of 2 quarters · filed 2026-02-24 | $2.76B derived: sum of 3 quarters · filed 2026-02-24 | $3.71B 10-K · filed 2026-02-24 |
| 2024-09-30 | $923.00M 10-Q · filed 2025-11-10 | $1.86B derived: sum of 2 quarters · filed 2025-11-10 | $2.82B 10-Q · filed 2025-11-10 | $3.73B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $939.00M 10-Q · filed 2025-08-06 | $1.90B 10-Q · filed 2025-08-06 | $2.81B derived: sum of 3 quarters · filed 2026-02-24 | $3.72B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $957.00M 10-Q · filed 2025-05-02 | $1.87B derived: sum of 2 quarters · filed 2026-02-24 | $2.78B derived: sum of 3 quarters · filed 2026-02-24 | $3.75B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $915.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.82B derived: sum of 2 quarters · filed 2026-02-24 | $2.79B derived: sum of 3 quarters · filed 2026-02-24 | $3.75B 10-K · filed 2026-02-24 |
| 2023-09-30 | $907.00M 10-Q · filed 2024-11-01 | $1.88B derived: sum of 2 quarters · filed 2024-11-01 | $2.83B 10-Q · filed 2024-11-01 | |
| 2023-06-30 | $968.00M 10-Q · filed 2024-08-07 | $1.93B 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $3.88B 10-K/A · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |